192 related articles for article (PubMed ID: 23357134)
1. Nicotinic acid as a lipid-modifying drug--a review.
Julius U; Fischer S
Atheroscler Suppl; 2013 Jan; 14(1):7-13. PubMed ID: 23357134
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
Shepherd J; Betteridge J; Van Gaal L;
Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866
[TBL] [Abstract][Full Text] [Related]
5. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Parhofer KG
Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
[TBL] [Abstract][Full Text] [Related]
6. [Multimodal therapy of dyslipidemia].
Stahn A; Hanefeld M
Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
[TBL] [Abstract][Full Text] [Related]
7. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
8. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).
Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
Int J Clin Pract; 2007 Nov; 61(11):1914-21. PubMed ID: 17935550
[TBL] [Abstract][Full Text] [Related]
9. [Niacin--an additive therapeutic approach for optimizing lipid profile].
Wieneke H; Schmermund A; Erbel R
Med Klin (Munich); 2005 Apr; 100(4):186-92. PubMed ID: 15834527
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
[TBL] [Abstract][Full Text] [Related]
12. [Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia].
Restrepo Valencia CA; Cruz J
Nefrologia; 2008; 28(1):61-6. PubMed ID: 18336133
[TBL] [Abstract][Full Text] [Related]
13. What restricts the clinical use of nicotinic acid?
Kei A; Liberopoulos EN; Elisaf MS
Curr Vasc Pharmacol; 2011 Jul; 9(4):521-30. PubMed ID: 21314634
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
[TBL] [Abstract][Full Text] [Related]
15. Nicotinic acid in the treatment of hyperlipidaemia.
Drexel H
Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():5-6. PubMed ID: 18001312
[TBL] [Abstract][Full Text] [Related]
16. Niacin for dyslipidemia: considerations in product selection.
McKenney J
Am J Health Syst Pharm; 2003 May; 60(10):995-1005. PubMed ID: 12789870
[TBL] [Abstract][Full Text] [Related]
17. Niacin: chemical forms, bioavailability, and health effects.
MacKay D; Hathcock J; Guarneri E
Nutr Rev; 2012 Jun; 70(6):357-66. PubMed ID: 22646128
[TBL] [Abstract][Full Text] [Related]
18. A case for immediate-release niacin.
Bassan M
Heart Lung; 2012; 41(1):95-8. PubMed ID: 21414665
[TBL] [Abstract][Full Text] [Related]
19. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
Goumas GS
Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
[TBL] [Abstract][Full Text] [Related]
20. Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
Zeman M; Vecka M; Perlík F; Hromádka R; Staňková B; Tvrzická E; Žák A
Med Sci Monit; 2015 Jul; 21():2156-62. PubMed ID: 26210594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]